Montai Therapeutics
Montai is a pioneering drug company focused on the predictable discovery of small molecule drugs for chronic diseases. By leveraging machine learning, biology, and diverse untapped chemistry, particularly Anthromolecule™ compounds, Montai aims to create effective oral medicines that address complex biological targets. Their CONECTA™ platform enhances drug discovery efficiency, enabling the identification and optimization of promising drug leads. With a commitment to improving health outcomes, Montai is positioned to transform the treatment landscape for chronic diseases, addressing significant unmet patient needs.
Montai Therapeutics
Montai is a pioneering drug company focused on the predictable discovery of small molecule drugs for chronic diseases. By leveraging machine learning, biology, and diverse untapped chemistry, particularly Anthromolecule™ compounds, Montai aims to create effective oral medicines that address complex biological targets. Their CONECTA™ platform enhances drug discovery efficiency, enabling the identification and optimization of promising drug leads. With a commitment to improving health outcomes, Montai is positioned to transform the treatment landscape for chronic diseases, addressing significant unmet patient needs.
TL;DR
Founded: 2022
Headquarters: Cambridge, Massachusetts
Focus: Small-molecule Anthromolecule medicines and Bioactivity Atlas for chronic diseases
Series A: $50M led by Flagship Pioneering (Dec 2022)
Team size (reported): ~61 employees
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Drug discovery for chronic diseases; improving predictability and repeatability of small-molecule therapeutic development.
Founded
2022
Industry
Biotechnology
Tech Stack
Funding Track Record
$50,000,000
Investor Signal
“Flagship Pioneering lead-backed”